Safety information
Indication
- JASCAYD® is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
- JASCAYD® is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF).
* Most cases of diarrhoea were grade 1 or 2 in Common Terminology Criteria for Adverse Events. Grade 1: increase of <4 stools per day; Grade 2: increase of 4–6 stools per day.6,7
† JASCAYD® is not recommended in patients with severe hepatic impairment.3
Most frequent adverse events in FIBRONEERTM-ILD trial
List of adverse events that occurred in ≥10% of patients with JASCAYD® ± nintedanib at end-of-trial analysis.8
Adverse event | Placebo ± nintedanib, n = 392 | JASCAYD® 18 mg ± nintedanib, n = 391 |
|---|---|---|
Diarrhoea | 26 (102) | 37 (145) |
Cough | 16 (61) | 17 (65) |
Upper respiratory tract infection | 17 (66) | 14 (53) |
Weight decreased | 8 (32) | 14 (56) |
COVID-19 | 16 (62) | 13 (51) |
Nasopharyngitis | 13 (49) | 13 (49) |
Pneumonia | 10 (41) | 13 (51) |
Nausea | 7 (28) | 12 (47) |
Anxiety | 11 (42) | 12 (45) |
Condition aggravated | 18 (71) | 11 (43) |
Depression | 13 (50) | 11 (44) |
Dyspnoea | 11 (43) | 10 (41) |
Please refer to the JASCAYD® Summary of Product Characteristics for further information.3
Most frequent adverse events in FIBRONEERTM-IPF trial
List of adverse events that occurred in ≥10% of patients with JASCAYD® ± background AF at end-of-trial analysis.9
Adverse event | Placebo ± background AF, n = 393 | JASCAYD® 18 mg ± background AF, n = 392 |
|---|---|---|
Diarrhoea | 18 (72) | 42 (166) |
Cough | 19 (74) | 17 (68) |
COVID-19 | 15 (57) | 15 (57) |
Upper respiratory tract infection | 11 (44) | 14 (56) |
Weight decreased | 10 (38) | 12 (48) |
Nasopharyngitis | 13 (50) | 11 (45) |
Dyspnoea | 16 (63) | 11 (42) |
Condition aggravated | 13 (52) | 11 (45) |
Decreased appetite | 7 (27) | 10 (40) |
Bronchitis | 10 (39) | 9 (35) |
Please refer to the JASCAYD® Summary of Product Characteristics for further information.3
Important safety information3
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Excipients: Lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, hypromellose 2910, talc, mannitol, macrogol 8000, iron oxide red (E172), iron oxide black (E172).
Drug interactions
Effects of other drugs on JASCAYD®
- Strong CYP3A inhibitors: Reduce the dosage of JASCAYD® to 9 mg twice daily (BID) when used concomitantly with strong CYP3A inhibitors.
- Moderate or strong CYP3A inducers: The recommended dosage of JASCAYD® is 18 mg BID and must not be reduced to 9 mg BID when used concomitantly with strong or moderate CYP3A inducers.
- Pirfenidone: Concomitant use of JASCAYD® with pirfenidone decreased JASCAYD® exposure by approximately 50%. Recommended dosage of JASCAYD® is 18 mg BID when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg BID.
Precautions
- Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Use in specific populations
- Renal impairment: Use of JASCAYD® is not recommended in patients with end stage renal disease (eGFR<15 mL/minute/1.73 m2).
- No dose adjustment is necessary in patients with mild, moderate, or severe renal impairment (eGFR≥15 and <90 mL/minute/1.73 m2, based on CKD-EPI formula).
- Hepatic impairment: Use of JASCAYD® is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.
- No dose adjustment is necessary in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.
Fertility, pregnancy and lactation
- Contraception: Females of reproductive potential should be advised to avoid becoming pregnant and to use effective contraceptive methods during treatment with JASCAYD®.
- Pregnancy: JASCAYD® is not recommended during pregnancy. Advise female patients to notify their healthcare provider if they become pregnant or suspect they may be pregnant during therapy with JASCAYD®. Advise pregnant women and females of reproductive potential of the potential risk of foetal loss.
- Breast-feeding: A risk to the breast-fed infant cannot be excluded. Breast-feeding should be discontinued during treatment with JASCAYD®.
- Fertility: There are no data on the impact of JASCAYD® in human fertility.
Adverse reactions
MedDRA System | MedDRA term | Frequency category |
|---|---|---|
Gastrointestinal disorders | Diarrhoea | Very common |
Nausea | Common | |
Metabolism and nutrition disorders | Decreased appetite | Common |
Investigations | Weight decreased | Very common |
Musculoskeletal and connective tissue disorders | Back pain | Common |
‡ Frequency categories: very common (≥1/10), common (≥1/100 – <1/10).
Please refer to the JASCAYD® Summary of Product Characteristics for further information.3